We are live on ! Find out more
Holocene Advisors

Holocene Advisors Portfolio holdings

AUM $41.5B
1-Year Est. Return 42.97%
This Fund
S&P 500
This Quarter Est. Return
+16.21%
1 Year Est. Return
+42.97%
3 Year Est. Return
+132.57%
5 Year Est. Return
+195.68%
10 Year Est. Return
AUM
$25.7B
AUM Growth
+$2.82B
Cap. Flow
-$314M
Cap. Flow %
-1.22%
Top 10 Hldgs %
15.35%
Holding
871
New
168
Increased
214
Reduced
287
Closed
191

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$327M
2
ABBV icon
AbbVie
ABBV
+$242M
3
DG icon
Dollar General
DG
+$229M
4
CLX icon
Clorox
CLX
+$227M
5
TXRH icon
Texas Roadhouse
TXRH
+$196M

Sector Composition

Rank Sector Weight
1 Healthcare 20.7%
2 Consumer Discretionary 17.67%
3 Technology 17.2%
4 Consumer Staples 11.96%
5 Industrials 10.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMZN icon
1
Amazon
AMZN
$2.94T
$699M 2.72%
4,601,436
+2,330,004
+103% +$327M
BKNG icon
2
Booking.com
BKNG
$160B
$593M 2.31%
4,180,050
+1,267,000
+43% +$158M
BSX icon
3
Boston Scientific
BSX
$69.2B
$456M 1.78%
7,885,159
+908,423
+13% +$48.5M
SHW icon
4
Sherwin-Williams
SHW
$89.7B
$352M 1.37%
1,128,232
-263,781
-19% -$70.9M
ISRG icon
5
Intuitive Surgical
ISRG
$133B
$326M 1.27%
965,911
+292,366
+43% +$87.2M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$79.1B
$317M 1.23%
360,480
+182,727
+103% +$150M
META icon
7
Meta Platforms (Facebook)
META
$1.5T
$306M 1.19%
865,302
-151,340
-15% -$49.3M
GSK icon
8
GSK
GSK
$103B
$305M 1.19%
8,224,548
+3,210,489
+64% +$115M
TGT icon
9
Target
TGT
$67.1B
$304M 1.18%
2,134,250
+1,274,613
+148% +$156M
AZN icon
10
AstraZeneca
AZN
$250B
$281M 1.1%
2,089,047
+851,241
+69% +$111M
UNP icon
11
Union Pacific
UNP
$176B
$274M 1.07%
1,114,216
+229,662
+26% +$50.5M
HLT icon
12
Hilton Worldwide
HLT
$73B
$273M 1.06%
1,498,153
-511,882
-25% -$83.5M
GPN icon
13
Global Payments
GPN
$23.9B
$265M 1.03%
2,089,334
+1,502,711
+256% +$174M
TYL icon
14
Tyler Technologies
TYL
$12.6B
$265M 1.03%
633,813
+11,897
+2% +$4.76M
TXRH icon
15
Texas Roadhouse
TXRH
$13.7B
$258M 1.01%
2,113,150
+1,832,693
+653% +$196M
ABBV icon
16
AbbVie
ABBV
$435B
$257M 1%
+1,660,493
New +$242M
DG icon
17
Dollar General
DG
$28B
$257M 1%
+1,891,921
New +$229M
DHI icon
18
D.R. Horton
DHI
$42.4B
$253M 0.99%
1,664,351
+412,691
+33% +$50.8M
MAS icon
19
Masco
MAS
$15.2B
$249M 0.97%
3,712,244
+671,536
+22% +$39M
SYY icon
20
Sysco
SYY
$40.3B
$246M 0.96%
3,358,330
+470,637
+16% +$32.5M
CLX icon
21
Clorox
CLX
$12.8B
$242M 0.94%
+1,700,101
New +$227M
ORCL icon
22
Oracle
ORCL
$416B
$234M 0.91%
2,219,664
+288,980
+15% +$31.5M
MDLZ icon
23
Mondelez International
MDLZ
$79.9B
$233M 0.91%
3,210,480
-802,292
-20% -$55M
CCEP icon
24
Coca-Cola Europacific Partners
CCEP
$48B
$230M 0.9%
3,441,305
+665,989
+24% +$40.7M
AXP icon
25
American Express
AXP
$236B
$228M 0.89%
1,218,713
-172,635
-12% -$27.8M

Similar funds

Holocene Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Holocene Advisors held 871 positions worth $25.7B, up 12% from $22.8B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Holocene Advisors's Q4 2023 filing shows 168 new, 214 increased, 287 reduced and 191 closed positions. Its largest new stake was AbbVie: 1,660,493 shares worth $257M. The largest sale was Procter & Gamble, an estimated $363M.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Holocene Advisors's largest Q4 2023 buy was AbbVie: 1,660,493 shares worth $257M.
  • Holocene Advisors added most to Amazon in Q4 2023, an estimated $327M increase.
  • Holocene Advisors's biggest Q4 2023 reduction was Microsoft, cutting an estimated $311M.
  • Holocene Advisors fully exited Procter & Gamble in Q4 2023, selling an estimated $363M.
  • Holocene Advisors's ten largest holdings make up 15% of its $25.7B portfolio in Q4 2023.
  • Holocene Advisors opened 168 new positions and closed 191 in Q4 2023.
  • Holocene Advisors's portfolio value rose 12% quarter-over-quarter to $25.7B.

Based on Holocene Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.